{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:35:57Z","timestamp":1770413757335,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.lungcan.2012.08.002","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T02:03:08Z","timestamp":1345773788000},"page":"127-132","source":"Crossref","is-referenced-by-count":21,"title":["Molecular aspects of thymic carcinoma"],"prefix":"10.1016","volume":"78","author":[{"given":"Annikka","family":"Weissferdt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.08.002_bib0005","series-title":"Tumours of the lung, pleura, thymus and heart","first-page":"148","year":"2004"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0010","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1309\/AJCP88FZTWANLRCB","article-title":"Thymic carcinoma: a clinicopathological and immunohistochemical study of 65 cases","volume":"138","author":"Weissferdt","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00194697","article-title":"Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21","volume":"426","author":"Hayashi","year":"1995","journal-title":"Virchows Arch"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/030089160809400613","article-title":"Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report","volume":"94","author":"Pedersini","year":"2008","journal-title":"Tumori"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0070","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0075","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"Aisner","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2012.05.108","article-title":"HER family receptor and ligand status in thymic carcinoma","author":"Weissferdt","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0100","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/JTO.0b013e3181f1cab3","article-title":"Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas","volume":"5","author":"Sasaki","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Str\u00f6bel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0115","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0130","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0145","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0160","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0165","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0170","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0175","first-page":"1621","article-title":"Aberrant methylation: common in thymic carcinomas, rare in thymomas","volume":"14","author":"Suzuki","year":"2005","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.lungcan.2012.08.002_bib0180","doi-asserted-by":"crossref","first-page":"e7273","DOI":"10.1371\/journal.pone.0007273","article-title":"High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)","volume":"4","author":"Gong","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0185","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","article-title":"Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors","volume":"17","author":"Breinig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.21277","article-title":"l-Type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas","volume":"99","author":"Kaira","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2559.1996.d01-540.x","article-title":"Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours","volume":"29","author":"Chen","year":"1996","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1699-0463.1998.tb01370.x","article-title":"Expression of bcl-2 in fetal thymus, thymomas and thymic carcinomas. Association with p53 expression and review of the literature","volume":"106","author":"Engel","year":"1998","journal-title":"APMIS"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0205","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/01.MP.0000038463.67854.84","article-title":"Proliferative activity and apoptosis in thymic epithelial neoplasms","volume":"15","author":"Hiroshima","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0210","first-page":"983","article-title":"Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors","volume":"10","author":"Tateyama","year":"1997","journal-title":"Mod Pathol"},{"issue":"6 Suppl. 11","key":"10.1016\/j.lungcan.2012.08.002_bib0215","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1053\/j.seminoncol.2006.10.006","article-title":"Targeted agents for adjuvant therapy of colon cancer","volume":"33","author":"de Gramont","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0220","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0230","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2165\/11205000-000000000-00000","article-title":"Imatinib: as adjuvant therapy for gastrointestinal stromal tumour","volume":"70","author":"Sanford","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ajcp\/104.4.375","article-title":"p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study","volume":"104","author":"Tateyama","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0245","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/JTO.0b013e31820b9b35","article-title":"Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and \u03b2 III-tubulin in thymic epithelial tumors","volume":"6","author":"Kaira","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.lungcan.2011.04.001","article-title":"Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors","volume":"74","author":"Kaira","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0255","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0002-9440(10)63031-3","article-title":"Thymic epithelial tumors can develop along two different pathogenetic pathways","volume":"159","author":"Zhou","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0260","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9440(10)64536-1","article-title":"Recurrent genetic aberrations in thymoma and thymic carcinoma","volume":"157","author":"Zettl","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0270","first-page":"3327","article-title":"Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma","volume":"51","author":"Kubonishi","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0275","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/PAS.0b013e31815a3900","article-title":"NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract","volume":"32","author":"Stelow","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0280","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3","article-title":"Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course","volume":"92","author":"Vargas","year":"2001","journal-title":"Cancer"},{"issue":"August (8)","key":"10.1016\/j.lungcan.2012.08.002_bib0285","first-page":"1253","article-title":"Successful treatment of a child with t(15;19)-positive tumor","volume":"33","author":"Mertens","year":"2009","journal-title":"Pediatr Blood Am J Surg Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0290","first-page":"1015","article-title":"NUT midline carcinoma of the parotid gland with mesenchymal differentiation","volume":"49","author":"den Bakker","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0295","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2350\/09-10-0727-CR.1","article-title":"NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic\/hepatic primary","volume":"13","author":"Shehata","year":"2010","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0300","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0165-4608(00)00336-8","article-title":"A novel t(1;8)(p13;p11) in a thymic carcinoma with unusual giant cell features and renal metastasis","volume":"124","author":"Sait","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.hoc.2008.03.002","article-title":"Thymic carcinoma: current concepts and histologic features","volume":"22","author":"Moran","year":"2008","journal-title":"Hematol Oncol N Am"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0315","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/00000478-199708000-00008","article-title":"Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity","volume":"21","author":"Dorfman","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.lungcan.2012.08.002_bib0320","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/PAS.0b013e3182260735","article-title":"Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis","volume":"35","author":"Weissferdt","year":"2011","journal-title":"Am J Surg Pathol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T03:02:36Z","timestamp":1562122956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212004679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0169500212004679"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.08.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}